ALX Oncology Holdings Inc.
NASDAQ:ALXOBiotechnology
-$0.03 today
- Market cap
- $134.14M
- Beta
- 0.45
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$1.64
Volume 0.56M
Average 1.07M
ALXO Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
ALX Oncology Holdings Inc.NASDAQ: ALXO
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $150K fell 28.9% year over year, behind the -25.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.7% from the prior quarter. Over 3 fiscal years it compounded at +27.3% a year.
Context
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -28.9% toward the trailing-twelve-month pace of -25.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 706K USD
- Year-over-year change
- -19.0%
- 4-year CAGR
- +92.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 706K | -19.0% |
| FY2024 | 2024-12-31 | 872K | +4.3% |
| FY2023 | 2023-12-31 | 836K | +144.4% |
| FY2022 | 2022-12-31 | 342K | +570.6% |
| FY2021 | 2021-12-31 | 51K | — |
Depreciation & Amortization vs competitors
How ALXO compares with its peers on the latest reported figures
- ALXO's LTM Mar 2026 depreciation & amortization of $645K is the lowest of the 8 companies compared; the peer median is $7.54M.
- Its year-over-year change of -25.8% is the lowest of 8, against a peer median of +0.8%.
- Over three fiscal years its annual growth of +27.3% compares with a peer median of +20.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.23M | +0.4% | +51.6% | — | |
| LTM Mar 2026 | $8.34M | +0.8% | +30.7% | 19.4% | |
| LTM Jun 2026 | $8.23M | +1.6% | +40.8% | 7.8% | |
| LTM Mar 2026 | $7.54M | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $5.92M | -17.6% | +20.3% | 9.3% | |
| LTM Mar 2026 | $3.54M | +69.2% | +4.6% | 11.0% | |
| LTM Mar 2026 | $3.06M | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| Peer median (excluding ALXO) | $7.54M | +0.8% | +20.3% | 11.0% | |
Competitors are the stored peer set for ALXO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 60.17M | 98.4M | 141.8M | 116.37M | 77M |
| Selling, General & Admin | 23.39M | 29.04M | 28.48M | 26.09M | 23.85M |
| Operating Expenses | 83.56M | 127.44M | 170.28M | 142.47M | 104.02M |
| Depreciation & Amortization | 51K | 342K | 836K | 872K | 706K |
| EBITDA | (83.42M) | (122.84M) | (158.4M) | (132.25M) | (99.39M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (83.56M) | (127.44M) | (170.28M) | (142.47M) | (104.02M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 91 | 4.28M | 10.65M | 9.37M | 3.96M |
| Interest Expense | 13K | 238K | 1.57M | 1.73M | 1.6M |
| Other Income / Expenses | 71K | 4.02M | 9.47M | 7.62M | 2.33M |
| Income Before Tax | (83.48M) | (123.42M) | (160.81M) | (134.85M) | (101.7M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (21K) | 64K | 0 | 0 | 0 |
| Net Income | (83.46M) | (123.48M) | (160.81M) | (134.85M) | (101.7M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| EPS (Diluted) | (2.07) | (3.03) | (3.74) | (2.58) | (1.90) |
| Weighted Avg Shares | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
| Weighted Avg Shares (Diluted) | 40.31M | 40.7M | 42.99M | 52.17M | 53.66M |
ALX Oncology Holdings Inc.
NASDAQ:ALXO
Intrinsic Alpha fair value
Locked
Current Price
$0.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.